Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain

NCT01116661 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT01116661
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01116661 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Tumors of the Brain
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2010
Completion date
February 28, 2019
Enrollment
199 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioma